E2F1 Maintains Gastric Cancer Stemness Properties by Regulating Stemness-Associated Genes

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Gastric cancer (GC) remains a significant health concern with complex underlying mechanisms.
• Cancer stem cells (CSCs) are implicated in tumor progression, metastasis, and therapeutic resistance.
• Understanding the regulatory factors of GC stemness is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the role of E2F1 in maintaining gastric cancer stemness.
• To determine the clinical significance of E2F1 expression in GC patients.
• To explore E2F1's impact on chemoresistance and patient prognosis.

Main Methods:

• Tumor spheroid formation assays to enrich and assess stem-like cells.
• Western Blot and qRT-PCR to measure gene and protein expression.
• Lentivirus-mediated gene manipulation to alter E2F1 levels.
• Cell viability assays and TUNEL staining to evaluate 5-Fu sensitivity.
• Clinical data analysis and survival analysis using the KM plotter database.

Main Results:

• E2F1 expression is significantly elevated in GC tissues and correlates with tumor size, stage, and differentiation.
• Higher E2F1 levels are associated with worse overall survival in GC patients.
• E2F1 regulates stemness-associated genes (BMI1, OCT4, Nanog, CD44) and enhances tumor spheroid formation.
• E2F1 confers resistance to 5-Fluorouracil (5-Fu) chemotherapy in GC cells.
• Co-overexpression of E2F1 and stemness genes predicts poor prognosis.

Conclusions:

• E2F1 is a key regulator of gastric cancer stemness and progression.
• E2F1's role in maintaining stemness involves regulating genes like BMI1, OCT4, Nanog, and CD44.
• E2F1 expression serves as a potential prognostic biomarker for GC patients.
• Targeting E2F1 may offer a novel therapeutic strategy for gastric cancer.